Literature DB >> 17534951

Mild Parkinsonian signs: An overview of an emerging concept.

Elan D Louis1, David A Bennett.   

Abstract

Mild Parkinsonian signs (MPS) include gait and balance changes, rigidity, bradykinesia, and tremor. MPS can occur commonly during the clinical examination of older people who do not have known neurological disease, with prevalence estimates for MPS as a whole ranging from 15% to 95%. MPS are generally progressive and they are coupled with functional difficulties, impaired gait and balance, and increased risks of mild cognitive impairment, dementia, and mortality. The mechanistic basis for these signs is unclear, but is likely to be multifactorial, with possible factors including an age-associated decline in dopaminergic nigrostriatal activity, the early development of neurodegenerative (Lewy body or Alzheimer's type) pathologies in the basal ganglia, or the accumulation of vascular pathology in the brain. It would be valuable to identify those individuals with MPS who are at increased risk for the development of future Alzheimer's disease, full-blown Parkinson's disease, or strokes, and to develop therapeutic strategies to intervene to lessen the likelihood of MPS-related morbidity and mortality. (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Year:  2007        PMID: 17534951     DOI: 10.1002/mds.21433

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  60 in total

1.  Premotor Parkinson's disease: concepts and definitions.

Authors:  Andrew Siderowf; Anthony E Lang
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

2.  Prognostic significance of the short physical performance battery in older patients discharged from acute care hospitals.

Authors:  Andrea Corsonello; Fabrizia Lattanzio; Claudio Pedone; Sabrina Garasto; Irma Laino; Silvia Bustacchini; Luigi Pranno; Bruno Mazzei; Giuseppe Passarino; Raffaele Antonelli Incalzi
Journal:  Rejuvenation Res       Date:  2011-10-17       Impact factor: 4.663

Review 3.  The neurobiology of falls.

Authors:  Alfonso Fasano; Meir Plotnik; Francesco Bove; Alfredo Berardelli
Journal:  Neurol Sci       Date:  2012-06-05       Impact factor: 3.307

4.  Estimation of Parkinson's disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach.

Authors:  O Chillag-Talmor; N Giladi; S Linn; T Gurevich; B El-Ad; B Silverman; N Friedman; C Peretz
Journal:  J Neurol       Date:  2012-07-07       Impact factor: 4.849

5.  Parkinsonian signs are a risk factor for falls.

Authors:  Nabila Dahodwala; Chinwe Nwadiogbu; Whitney Fitts; Helen Partridge; Jason Karlawish
Journal:  Gait Posture       Date:  2017-04-04       Impact factor: 2.840

Review 6.  Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for "mild cognitive impairment" and biomarkers.

Authors:  Alexander I Tröster
Journal:  Neuropsychol Rev       Date:  2008-03-06       Impact factor: 7.444

7.  Cerebrovascular disease pathology and parkinsonian signs in old age.

Authors:  Aron S Buchman; Sue E Leurgans; Sukriti Nag; David A Bennett; Julie A Schneider
Journal:  Stroke       Date:  2011-09-01       Impact factor: 7.914

Review 8.  Management of Gait Changes and Fall Risk in MCI and Dementia.

Authors:  Gilles Allali; Joe Verghese
Journal:  Curr Treat Options Neurol       Date:  2017-09       Impact factor: 3.598

9.  Parkinson's Disease-Related Motor and Nonmotor Symptoms in the Lancaster Amish.

Authors:  Michael D F Goldenberg; Xuemei Huang; Honglei Chen; Lan Kong; Teodor T Postolache; John W Stiller; Katherine A Ryan; Mary Pavlovich; Toni I Pollin; Alan R Shuldiner; Richard B Mailman; Braxton D Mitchell
Journal:  Neuroepidemiology       Date:  2020-07-31       Impact factor: 3.282

10.  Locus coeruleus neuron density and parkinsonism in older adults without Parkinson's disease.

Authors:  Aron S Buchman; Sukriti Nag; Joshua M Shulman; Andrew S P Lim; Veronique G J M VanderHorst; Sue E Leurgans; Julie A Schneider; David A Bennett
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.